SO‘GLIQNI SAQLASHNING YANGI DAVRI-SHAXSIYLASHTIRILGAN TIBBIYOT HAQIDA
Article Sidebar
Main Article Content
Abstract
Bugungi kunda sog‘liqni saqlash tizimi tez sur’atlar bilan rivojlanib, individual yondashuvga asoslangan shaxsiylashtirilgan tibbiyot tamoyillari keng qo‘llanilmoqda. Ushbu yondashuv har bir bemorning genetik, biologik va hayot tarziga oid xususiyatlarini inobatga olib, davolash usullarini moslashtirishga imkon yaratadi. Tezisimizda shaxsiylashtirilgan tibbiyotning mohiyati, uning afzalliklari va rivojlanish istiqbollari tahlil qilinadi.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
Mariantonia Di Sanzo, Luigi Cipolloni, Marina Borro, Raffaele La Russa, Alessandro Santurro, Matteo Scopetti, Maurizio Simmaco and Paola Frati. “Clinical Applications of Personalized Medicine: A New Paradigm and Challenge” Current Pharmaceutical Biotechnology, Volume 18, Issue 3, Mar 2017, p. 194 – 203
Sunil Mathur and Joseph Sutton. “Personalized medicine could transform healthcare” (Review). Biomedical Reports 7: 3-5, 2017
Mukesh Verma. “Personalized Medicine and Cancer” Journal of Personalized Medicine ISSN 2075-4426
Sarasqueta, F.; Lijnshoten, G.; Lemmens, V.E.; Rutten, H.J.; van den Brule, A.J. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers? Mol. Diagn. Ther. 2011, 15, 277–283.
Castillo-Fernandez, O.; Santibanez, M.; Bauza, A.; Calderillo, G.; Castro, C.; Herrera, R.; Serrano, A.; Arrieta, O.; Herrera, L.A. Methylenetetrahydrofolatereductase polymorphism (677 J. Pers. Med. 2012, 2 13 C-T) predicts long time to progression in metastatic colon cancer treated with 5fluorouracil and folinic acid. Arch. Med. Res. 2010, 41, 430–433.
Boni, V.; Zarate, R.; Villa, J.C.; Bandrés, E.; Gomez, M.A.; Maiello, E.; Garcia-Foncillas, J.; Aranda, E. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics 2011, 11, 429–436 166